Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice

Journal of Controlled Release

Volumn 87, Issue 1-3, 2003, Pages 49-56

  Lee, Kuen Yong ^a   Peters, Martin C ^a   Mooney, David J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Hydrogel; Vascular endothelial growth factor

Indexed keywords

ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; GRANULATION TISSUE; HYDROGEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SUBCUTANEOUS TISSUE; THICKNESS;

EID: 0037459004     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00349-8     Document Type: Conference Paper

References (37)

1. Cotran R.S., Kumar V., Collins T. Pathological Basis of Disease. 1999;W.B. Saunders Co, Philadelphia, PA.
2. Solomon A.J., Gersh B.J. Management of chronic stable angina: Medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery - lessons from the randomized trials. Ann. Intern. Med. 128:1998;216-223.
3. Pu L.Q., Sniderma A.D., Brassard R., Lachapelle K.J., Graham A.M., Lisbona R., Symes J.F. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation. 88:1993;208-215.
4. Post M.J., Laham R., Selleke F.W., Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 49:2001;522-531.
5. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis? Cell. 87:1996;1153-1155.
6. Schumacher B., Pecher P., von Specht B.U., Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors - first clinical results of a new treatment of coronary heart disease. Circulation. 97:1998;645-650.
7. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., Gold J.P., Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery - results of a phase I randomized, double-blind, placebo-controlled trial. Circulation. 100:1999;1865-1871.
8. Langer R., Vacanti J.P. Tissue engineering. Science. 260:1993;920-926.
9. Mooney D.J., Mikos A.G. Growing new organs. Sci. Am. 280:1999;60-65.
10. Xie M.H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., Foster J., Liang J., Brush J., Gu Q.M., Hillan K., Goddard A., Gurney A.L. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine. 11:1999;729-735.
11. Battler A., Scheinowitz M., Bor A., Hasdai D., Vered Z., Disegni E., Vardabloom N., Nass D., Engelberg S., Eldar M., Belkin M., Savion N.J. Intracoronary injection of basic fibroblast growth-factor enhances angiogenesis in infarcted swine myocardium. Am. Coll. Cardiol. 22:1993;2001-2006.
12. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med. 5:1999;1359-1364.
13. Park J.E., Keller G.A., Ferrara N. Vascular endothelial growth-factor (VEGF) isoforms - differential deposition into the subepithelial extracellular-matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4:1993;1317-1326.
14. Nor J.E., Christensen J., Mooney D.J., Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:1999;375-384.
15. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22.
16. Lazarous D.F., Shou M., Scheinowitz M., Hodge E., Thirumurti V., Kitsiou A.N., Stiber J.A., Lobo A.D., Hunsberger S., Guetta E., Epstein S.E., Unger E.F. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
17. Whalen G.F., Shing Y., Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors. 1:1989;157-164.
18. Mazue G., Bertolero F., Jacob C., Sarmientos P., Roncucci R. Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann. NY Acad. Sci. 638:1991;329-340.
19. Mazue G., Bertolero F., Garofano L., Brughera M., Carminati P. Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). Toxicol. Lett. 64-65:1992;329-338.
20. Mazue G., Newman A.J., Scampini G., Dellatorre P., Hard G.C., Iatropoulos M.J., Williams G.M., Bagnasco S.M. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE-26184, human basic fibroblast growth factor. Toxicol. Pathol. 21:1993;490-501.
21. Goncalves L.M., Epstein S.E., Piek J.J. Controlling collateral development: the difficult task of mimicking mother nature. Cardiovasc. Res. 49:2001;495-496.
22. Peters M.C., Mooney D.J. Growth factor delivery from tissue engineering matrices: inducing angiogenesis to enhance transplanted cell engraftment. Park K., Mrsny R.J. Controlling Drug Delivery: Designing Technologies for the Future. 2000;157-167 American Chemical Society, Washington.
23. Gombotz W.R., Pettit D.K. Biodegradable polymers for protein and peptide drug delivery. Bioconjug. Chem. 6:1995;332-351.
24. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nature Biotech. 16:1998;153-157.
25. Edelman E.R., Nugent M.A., Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. USA. 90:1993;1513-1517.
26. Edelman E.R., Mathiowitz E., Langer R., Klagsbrun M. Controlled and modulated release of basic fibroblast growth-factor. Biomaterials. 12:1991;619-626.
27. Downs E.C., Robertson N.E., Riss T.L., Plunkett M.L. Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. J. Cell Physiol. 152:1992;422-429.
28. Peters M.C., Isenberg B.C., Rowley J.A., Mooney D.J. Release from alginate enhances the biological activity of vascular endothelial growth factor. J. Biomat. Res. - Polym. Edn. 9:1998;1267-1278.
29. Lee K.Y., Peters M.C., Anderson K.W., Mooney D.J. Controlled growth factor release from synthetic extracellular matrices. Nature. 408:2000;908-1000.
30. Lee K.Y., Mooney D.J. Hydrogels for tissue engineering. Chem. Rev. 101:2001;1869-1880.
31. Cleland J.L., Duenas E.T., Park A., Daugherty A., Kahn J., Kowalski J., Cuthbertson A. Development of poly-(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control. Rel. 72:2001;13-24.
32. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nature Biotech. 19:2001;1029-1034.
33. Rowley J.A., Mooney D.J. Alginate type and RGD density control myoblast phenotype. J. Biomed. Mater. Res. 60:2002;217-223.
34. Epstein S.E., Fuchs S., Zhou Y.F., Baffour R., Kornowski R. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc. Res. 49:2001;532-542.
35. Yoshida A., Anand-Apte B., Zetter B.R. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors. 13:1996;57-64.
36. Bauters C., Asahara T., Zheng L.P., Takeshita S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth-factor. J. Vasc. Surg. 21:1995;314-325.
37. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog. Growth Factor Res. 1:1989;207-235.